Natural Product (NP) Details
General Information of the NP (ID: NP8268) | |||||
---|---|---|---|---|---|
Name |
Curcumol
|
||||
Synonyms |
(-)-Curcumol; 4871-97-0; UNII-9190RTN07X; 9190RTN07X; MFCD00272163; (3S,3aS,5S,6R,8aS)-Octahydro-3-methyl-8-methylene-5-(1-methylethyl)-6H-3a,6-epoxyazulen-6-ol; 5,8-Epoxy-10(14)-guaien-8-ol; ( -)-Curcumol; CHEMBL4303567; SCHEMBL22404924; HY-N0104; ( -)-Curcumol, analytical standard; s2407; ZINC70466453; AKOS022168205; CCG-266844; NCGC00346607-02; BS-16857; V0174; 871C970; Q-100546; Q27271386; (1S,2S,5S,8R,9S)-2-methyl-6-methylidene-9-propan-2-yl-11-oxatricyclo[6.2.1.01,5]undecan-8-ol; (3S-(3alpha,3aalpha,5alpha,6alpha,8abeta))-Octahydro-3-methyl-8-methylene-5-(1-methylethyl)-6H-3a,6-epoxyazulen-6-ol; 6H-3a,6-Epoxyazulen-6-ol, octahydro-3-methyl-8-methylene-5-(1-methylethyl)-, (3S,3aS,5S,6R,8aS)-
Click to Show/Hide
|
||||
Species Origin | Halicephalobus sp. hali_val ... | Click to Show/Hide | |||
Halicephalobus sp. hali_val | |||||
Disease | Mucositis [ICD-11: CA00] | Phase 3 | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C15H24O2
|
||||
PubChem CID | |||||
Canonical SMILES |
CC1CCC2C13CC(C(O3)(CC2=C)O)C(C)C
|
||||
InChI |
1S/C15H24O2/c1-9(2)13-8-14-11(4)5-6-12(14)10(3)7-15(13,16)17-14/h9,11-13,16H,3,5-8H2,1-2,4H3/t11-,12-,13-,14-,15+/m0/s1
|
||||
InChIKey |
QRMPRVXWPCLVNI-YYFQZIEXSA-N
|
||||
CAS Number |
CAS 4871-97-0
|
||||
Herb ID | |||||
ETMC ID | |||||
SymMap ID | |||||
TCMSP ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | NQO2 | Molecule Info | |||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
NCI-H358 | CVCL_1559 | Lung adenocarcinoma | Homo sapiens | |||
NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
In-vivo Model | BALB/c nude mice (5-week-old) were subcutaneously inoculated with A549 cells (1*106). | |||||
Experimental
Result(s) |
Curcumol overcomes TRAIL resistance of non-small cell lung cancer by targeting NRH:Quinone Oxidoreductase 2 (NQO2). |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Receptor-interacting protein 1 (RIPK1) | Molecule Info | [3] | |
Receptor-interacting protein 3 (RIPK3) | Molecule Info | [3] |


